GLP-1 Receptor Agonist Market - By Drug Class (Semaglutide, Dulaglutide, Liraglutide, Exenatide), By Route of Administration (Parenteral), By Application (Type 2 Diabetes, Obesity), By Distribution (Hospital, Retail), Global Forecast, 2023 – 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationGLP-1 Receptor Agonist Market - By Drug Class (Semaglutide, Dulaglutide, Liraglutide, Exenatide), By Route of Administration (Parenteral), By Application (Type 2 Diabetes, Obesity), By Distribution (Hospital, Retail), Global Forecast, 2023 – 2032
GLP-1 Receptor Agonist Market Size
GLP-1 Receptor Agonist Market size was evaluated to be around USD 22.4 billion in 2022 and is anticipated to exhibit sustainable growth at a CAGR of around 9.6% during the forecast period, i.e., from 2023 to 2032. The growth is attributed primarily to factors such increasing prevalence of chronic diseases such as diabetes and obesity, increasing R&D activities for developing novel therapeutics, advancement in formulation of oral GLP-1 receptor agonist, and increasing awareness about diagnosis and treatment option for diabetes.
Glucagon-like peptide-1 (GLP-1) receptor agonists bind and activate the GLP-1 receptor, stimulating glucose-dependent insulin release from the pancreatic islets and slowing gastric emptying. GLP-1 is an important gut-derived hormone that enhances insulin secretion. In the presence of elevated glucose, it increases glucose-dependent insulin synthesis and the in vivo secretion of insulin from pancreatic beta cells. In addition to this, GLP-1 suppresses glucagon secretion, reduces food intake via the reduction of appetite, and promotes beta cell proliferation.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| GLP-1 Receptor Agonist Market Size in 2022 | USD 22.4 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 9.6% |
| 2032 Value Projection | USD 55.8 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 160 |
| Tables, Charts & Figures | 280 |
| Segments covered | Drug class, Route of administration, Application, Distribution channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
GLP-1 receptor agonists are one of the antidiabetics and are suitable initial therapy for patients with type 2 diabetes and those who are at high risk of cardiovascular diseases. In addition to these, it can be used as an initial therapy for high-risk heart failure or chronic kidney disease. GLP-1 receptor agonist therapies facilitate restoring insulin secretory functions, improving glycemic control, and reducing weight in type 2 diabetes patients.
COVID-19 Impact
During the COVID-19 pandemic, the market for GLP-1 receptor agonists, used to treat type 2 diabetes, faced challenges. Lockdowns and travel restrictions disrupted supply chains, making it difficult to get raw materials and deliver finished products. Despite these obstacles, the market got a boost because people with type 2 diabetes are at higher risk of severe COVID-19. Studies showed that GLP-1 receptor agonists may help protect against COVID-19 by increasing a protein called ACE2 in the lungs and heart. They also showed promise in treating acute lung injury related to COVID-19. This positive news has helped boost the overall diabetes therapeutics market, including GLP-1 receptor agonists, insulin delivery devices, diabetes care devices, and digital diabetes management tools. So, while the pandemic did present some challenges, it has ultimately led to a growing market for diabetes treatments.
Later, as COVID instances decreased, the market experienced considerable growth with increasing R&D activities, new product launches, and continuous support and investments from the government.
GLP-1 Receptor Agonist Market Trends
The prevalence of chronic diseases like diabetes, cardiovascular diseases, obesity, and many others has been rapidly increasing over the past few decades. The prevalence of diabetes is increasing at an alarming rate all over the globe. For instance, according to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, in 2021, approximately 537 million adults were living with diabetes, and it is estimated that by 2030, the number of diabetic patients will reach 643 million and by 2045, 783 million worldwide. According to the IDF, in 2021, diabetes is expected to cause 6.7 million deaths. Among type 1 and type 2 diabetes, the most common is type 2, which usually occurs in adults.
Obesity is a major global issue that can harm our hearts, kidneys, livers, and brains. It can trigger other illnesses like diabetes, heart disease, stroke, and cancer. Shockingly, in 2022, over a billion people worldwide were obese, including 650 million adults, 340 million teens, and 39 million children, according to the World Health Organization. And these numbers are still climbing. Dealing with these chronic diseases is becoming increasingly important. One way to combat diabetes and obesity is through medications called GLP-1 receptor agonists. These drugs are becoming more popular as the prevalence of diabetes and obesity continues to rise around the world.
Due to the rising prevalence and demand for novel therapeutics for treating diseases like diabetes, obesity, cardiovascular disorders and many others are boosting the growth of global market. The pharmaceutical companies are increasing the research and development activities for developing novel GLP-1 receptor agonist drugs in order to overcome the health and mental issues caused by obesity and diabetes.
GLP-1 Receptor Agonist Market Analysis
In the world of diabetes and weight loss drugs, there are many different types. One of the most important is called a GLP-1 receptor agonist. This type of drug works by mimicking a natural hormone in your body that helps control blood sugar and appetite. Among these drugs, semaglutide stands out as a real leader. It's used to help manage blood sugar levels in people with type 2 diabetes, and it can also help people lose weight. And because diabetes and obesity are becoming more and more common, the demand for semaglutide is growing rapidly.
Based on route of administration, the GLP-1 receptor agonist market is subdivided into parenteral and oral routes of administration. The parenteral segment held the highest market share in 2022 owing to the advantages offered such as immediate onset of action, better bioavailability, easy absorption of active form of medications and zero chances of interference. Many of the GLP-1 receptor agonist drugs are administered by parenteral routes; for instance, Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Exenatide (Bydureon, Byetta) are available in injections form.
When it comes to using GLP-1 receptor agonist (a type of medication), it's mainly used for three thingstreating type 2 diabetes, helping with weight loss in obese people, and other various purposes. Out of these three, treating type 2 diabetes was the most common use in 2022. That's because GLP-1 receptor agonists work by telling the body to release more insulin and stop releasing glucagon when blood sugar levels are too high. This helps keep blood sugar levels in check and can also lead to weight loss. The increase in type 2 diabetes cases, the need for better treatments, and the rising number of prescriptions for GLP-1 receptor agonist medications are all driving the growth of this particular segment of the market.
Based on distribution channel, the global GLP-1 receptor agonist market is subdivided into hospital, retail, and online pharmacies. Among the distribution channel segments, the hospital segment held the highest revenue share of the market in 2022. The large share of this segment can be attributed to the large patient pool towards hospital, wide availability of medicines in hospital pharmacies, and continuous availability of diabetes consultant in the hospitals.
Furthermore, the increasing prevalence of chronic diseases, development of new therapies for type 2 diabetes, increasing government initiatives in launching the new drugs, and need for long term treatment of chronic diseases like diabetes and obesity are expected to drive the growth of this segment.
The global market for GLP-1 receptor agonists, a class of drugs used to treat diabetes and obesity, is divided into several regionsNorth America (USA, Canada, Mexico) Europe (UK, Germany, France, Spain, Italy) Asia-Pacific (China, Japan, India, South Korea, Australia) Latin America (Brazil, Argentina, Mexico) Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa) In 2022, North America dominated the market, thanks toA high number of people with chronic diseases like diabetes and obesity Significant investments in research and development for new diabetes and obesity treatments The presence of leading pharmaceutical companies Advanced healthcare systems Over the next few years, the Asia-Pacific region is expected to grow the fastest. This is because more people are developing chronic diseases, and governments are investing more money in diagnosing and treating diabetes.
In North America segment, the U.S. accounted for the highest market share in 2022 due to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and increasing awareness and demand for GLP-1 receptor agonist products.
GLP-1 Receptor Agonist Market Share
The key players in GLP-1 receptor agonist market are
- Eli Lilly and Company
- Sanofi
- Novo-Nordisk A/S
- AstraZeneca
- Pfizer.Inc
- Amgen, Inc.
- Innovent Biologics, Inc.
- PegBio Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
GLP-1 Receptor Agonist Industry News
- In March 2023, NHS approved Wegovy, a weight loss injection which mimics the hormone glucagon-like peptide-1 (GLP-1) and suppresses appetite. The NHS will now offer Wegovy, known as semaglutide, to thousands of people living with obesity in England.
- In May 2022, US FDA approved Mounjaro (tirzepatide) injection of Eli Lilly and Company for treating type 2 diabetes patients. Mounjaro is once in a week GLP-1 receptor agonist.
The GLP-1 receptor agonist market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Drug Class
- Semaglutide
- Dulaglutide
- Liraglutide
- Exenatide
- Other drug classes
By Route of Administration
- Parenteral
- Oral
By Application
- Type 2 diabetes mellitus
- Obesity
- Other applications
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Switzerland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy